

Time	Contents	Speaker
9:30 ~ 10:00	Registration	
10:00 ~ 10:10	Opening remark by President of PAGK	
Young Scientist Session		Chair: Yusuke Tanigawara (PAGJa), Jun Shi (PCPC)
10:10 ~ 10:30	Modeling of Mycoplasma tuberculosis biomarkers for cure	Yookhwan Noh (PAGK)
10:30 ~ 10:50	Integrative Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Amenamevir (ASP2151) for Treatment of Recurrent Genital Herpes	Akitsugu Takada (PAGJa)
10:50 ~ 11:10	Model Based Meta-Analysis to Quantify and Compare the Efficacy of Non-hormonal Drugs on Menopausal Hot Flashes	Lujin Li (PCPC)
11:10 ~ 11:30	Dosing optimization in obesity using pharmacometrics approach: Population Pharmacokinetics and Pharmacodynamics of meropenem in non-obese, obese, and morbidly obese patients.	Eun Kyung Chung (PAGK)
11:30 ~ 11:50	Application of pharmacometrics in pediatric drug development, Wei Zhao, PharmD, PhD Department of Clinical Pharmacy, Shandong University	Wei Zhao (PCPC)
11:50 ~ 13:00	Lunch break	
Application Session		Chair: Dong-Seok Yim (PAGK), Hidefumi Kasai (PAGJa)
13:00 ~ 13:20	The application of pharmacometrics in individual therapy in China	Zheng Jiao (PCPC)
13:20 ~ 13:40	Population Pharmacodynamic Model for Bayesian Prediction of Myelosuppression Profiles Based on Routine Clinical Data after Gemcitabine and Carboplatin Treatment	Yoshitaka Yano (PAGJa)
13:40 ~ 14:00	Modeling and validating chronic pharmacological manipulation of circadian rhythms	Jaekyoung Kim (PAGK)
14:00 ~ 14:20	Application of PK/PD modeling and simulation in antiviral drug development	Kun Wang (PCPC)
14:20 ~ 14:40	Pharmacometrics in clinical practice: population PK analysis of febuxostat in patients with severe renal impairment	Daiki Hira (PAGJa)
14:40 ~ 15:20	Tea break & Poster standing	
Regulatory Session		Chair: Wei Lu (PCPC), Jung Mi Oh (PAGK)
15:20 ~ 15:40	The New Japanese Guideline on Population Pharmacokinetic and Pharmacodynamic Analysis.	Yusuke Tanigawara (PAGJa)
15:40 ~ 16:00	How to increase the number of population pharmacokinetic analysis reports submitted to MFDS in Korea	Howard Lee (PAGK)
16:00 ~ 16:20	Regulation of CFDA related to pharmacometrics	Qingshan Zheng (PCPC)
16:20 ~ 16:40	EMA regulations on modeling issues	JaeWoo Kim (PAGK)
16:40 ~ 17:00	Recent examples of impact of pharmacometrics in decision making	Jee Eun Lee (USA)
17:00 ~ 17:30	Discussion	
17:30 ~ 17:40	Closing remark by President of PAGJa and PCPC	
18:00 ~	Social event with dinner	